BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 8642852)

  • 21. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.
    Maslak PG; Weiss MA; Berman E; Yao TJ; Tyson D; Golde DW; Scheinberg DA
    Leukemia; 1996 Jan; 10(1):32-9. PubMed ID: 8558934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
    Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
    Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Results of induction treatment with idarubicin for acute nonlymphoblastic leukemia in adults].
    Hołowiecki J; Krzemień S; Rudzka E; Krawczyk M; Wojnar J; Hołowiecka B; Wacławik A; Wojciechowska M; Kachel L; Cedrych I
    Acta Haematol Pol; 1994; 25(3):221-30. PubMed ID: 7992594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
    Weick JK; Kopecky KJ; Appelbaum FR; Head DR; Kingsbury LL; Balcerzak SP; Bickers JN; Hynes HE; Welborn JL; Simon SR; Grever M
    Blood; 1996 Oct; 88(8):2841-51. PubMed ID: 8874180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.
    Lemez P; Maresová J
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):61-5. PubMed ID: 9768826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial.
    Heil G; Mitrou PS; Hoelzer D; Freund M; Link H; Ehninger G; Steinke B; Ohl S; Wandt H; Fackler-Schwalbe E
    Ann Hematol; 1995 Nov; 71(5):219-25. PubMed ID: 7492624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.
    Bassan R; Chiodini B; Zucchetti M; Lerede T; Cornelli PE; Cortelazzo S; Barbui T
    Haematologica; 1998 Jan; 83(1):27-33. PubMed ID: 9542320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Consolidation therapy with high-dose cytarabine and daunorubicin for prolonged disease free survival in acute myelocytic leukemia].
    Qiau Z; Wang C; Yang L
    Zhonghua Nei Ke Za Zhi; 1996 Aug; 35(8):545-8. PubMed ID: 9594148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
    Vogler WR; Velez-Garcia E; Omura G; Raney M
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
    [No Abstract]   [Full Text] [Related]  

  • 31. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).
    Ohno R; Kobayashi T; Morishima Y; Hiraoka A; Imai K; Asoh N; Tsubaki K; Tomonaga M; Takahashi I; Kodera K
    Leukemia; 1992; 6 Suppl 2():92-5. PubMed ID: 1578954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
    Wiernik PH; Banks PL; Case DC; Arlin ZA; Periman PO; Todd MB; Ritch PS; Enck RE; Weitberg AB
    Blood; 1992 Jan; 79(2):313-9. PubMed ID: 1730080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.
    Carella AM; Carlier P; Pungolino E; Resegotti L; Liso V; Stasi R; Montillo M; Iacopino P; Mirto S; Pagano L
    Leukemia; 1993 Feb; 7(2):196-9. PubMed ID: 8426473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
    Jehn U; Zittoun R; Suciu S; Fiere D; Haanen C; Peetermans M; Löwenberg B; Willemze R; Solbu G; Stryckmans P
    Haematol Blood Transfus; 1990; 33():277-84. PubMed ID: 1691132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia.
    Beksaç M; Arslan O; Koç H; Akan H; Ilhan O; Arat M; Ozcan M; Gürman G; Konuk N; Uysal A
    Med Oncol; 1998 Sep; 15(3):183-90. PubMed ID: 9819795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
    Zittoun R; Suciu S; Mandelli F; de Witte T; Thaler J; Stryckmans P; Hayat M; Peetermans M; Cadiou M; Solbu G; Petti MC; Willemze R
    J Clin Oncol; 1996 Jul; 14(7):2150-9. PubMed ID: 8683249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first.
    Anderlini P; Ghaddar HM; Smith TL; Pierce S; Kantarjian HM; O'Brien S; Keating MJ; Freireich EJ; Estey EH
    Leukemia; 1996 Jun; 10(6):964-9. PubMed ID: 8667653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
    Berman E; Heller G; Santorsa J; McKenzie S; Gee T; Kempin S; Gulati S; Andreeff M; Kolitz J; Gabrilove J
    Blood; 1991 Apr; 77(8):1666-74. PubMed ID: 2015395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous-infusion carboplatin in combination with idarubicin or mitoxantrone for high-risk acute myeloid leukemia: a randomised phase II study.
    Belhabri A; Thomas X; Troncy J; Assouline D; Michallet M; Wattel E; Tigaud JD; Blanc M; Fière D; Archimbaud E
    Leuk Lymphoma; 1999 Dec; 36(1-2):45-55. PubMed ID: 10613449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.